Literature DB >> 34359991

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies.

Christian von Loeffelholz1, Sina M Coldewey1,2,3, Andreas L Birkenfeld4,5,6.   

Abstract

5'AMP-activated protein kinase (AMPK) is known as metabolic sensor in mammalian cells that becomes activated by an increasing adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio. The heterotrimeric AMPK protein comprises three subunits, each of which has multiple phosphorylation sites, playing an important role in the regulation of essential molecular pathways. By phosphorylation of downstream proteins and modulation of gene transcription AMPK functions as a master switch of energy homeostasis in tissues with high metabolic turnover, such as the liver, skeletal muscle, and adipose tissue. Regulation of AMPK under conditions of chronic caloric oversupply emerged as substantial research target to get deeper insight into the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Evidence supporting the role of AMPK in NAFLD is mainly derived from preclinical cell culture and animal studies. Dysbalanced de novo lipogenesis has been identified as one of the key processes in NAFLD pathogenesis. Thus, the scope of this review is to provide an integrative overview of evidence, in particular from clinical studies and human samples, on the role of AMPK in the regulation of primarily de novo lipogenesis in human NAFLD.

Entities:  

Keywords:  adipose tissue; diacylglycerol; free fatty acids; insulin resistance; lipotoxicity; skeletal muscle; steatohepatitis; type 2 diabetes

Year:  2021        PMID: 34359991     DOI: 10.3390/cells10071822

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  6 in total

Review 1.  A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.

Authors:  Devaraj Ezhilarasan; Thangavelu Lakshmi
Journal:  Oxid Med Cell Longev       Date:  2022-05-11       Impact factor: 7.310

2.  Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice.

Authors:  Chian-Jiun Liou; Shu-Ju Wu; Szu-Chuan Shen; Li-Chen Chen; Ya-Ling Chen; Wen-Chung Huang
Journal:  Int J Mol Sci       Date:  2022-04-23       Impact factor: 6.208

3.  MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease.

Authors:  Wu Luo; Lin Ye; Xue-Ting Hu; Mei-Hong Wang; Min-Xiu Wang; Lei-Ming Jin; Zhong-Xiang Xiao; Jian-Chang Qian; Yi Wang; Wei Zuo; Li-Jiang Huang; Guang Liang
Journal:  Clin Transl Med       Date:  2022-03

4.  N-Octyl Caffeamide, a Caffeic Acid Amide Derivative, Prevents Progression of Diabetes and Hepatic Steatosis in High-Fat Diet Induced Obese Mice.

Authors:  Miao-Yi Wu; Chia-Chu Liu; Su-Chu Lee; Yueh-Hsiung Kuo; Tusty-Jiuan Hsieh
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

5.  A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity.

Authors:  Grit Zahn; Diana M Willmes; Nermeen N El-Agroudy; Christopher Yarnold; Richard Jarjes-Pike; Sabine Schaertl; Kay Schreiter; Wiebke Gehrmann; Andrea Kuan Cie Wong; Tommaso Zordan; Jörg König; Jens Jordan; Andreas L Birkenfeld
Journal:  Metabolites       Date:  2022-08-08

Review 6.  The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease.

Authors:  Christian von Loeffelholz; Johannes Roth; Sina M Coldewey; Andreas L Birkenfeld
Journal:  Biomedicines       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.